Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | FAAH | O00519 | 4/20 | 0.58 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.58 |
| ▸ | TERT | O14746 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | BLM | P54132 | 2/20 | 0.56 |
| ▸ | FABP4 | P15090 | 2/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.56 |
| ▸ | PPARG | P37231 | 2/20 | 0.56 |
| ▸ | PPARD | Q03181 | 2/20 | 0.56 |
| ▸ | PPARA | Q07869 | 2/20 | 0.56 |
| ▸ | GMNN | O75496 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5039239 | 1.00 | LMNA (0.68) | LMNAHSD17B10KMT2AMEN1ALDH1A1 | |
| SCHEMBL833160 | 1.00 | LMNA (0.68) | LMNAHSD17B10KMT2AMEN1ALDH1A1 | |
| SCHEMBL1302194 | 1.00 | LMNA (0.68) | LMNAHSD17B10KMT2AMEN1ALDH1A1 | |
| SCHEMBL5044800 | 1.00 | LMNA (0.68) | LMNAHSD17B10KMT2AMEN1ALDH1A1 | |
| SCHEMBL5361747 | 1.00 | LMNA (0.68) | LMNAHSD17B10KMT2AMEN1ALDH1A1 | |
| SCHEMBL22616793 | 1.00 | LMNA (0.68) | LMNAHSD17B10KMT2AMEN1ALDH1A1 | |
| SCHEMBL24450559 | 1.00 | LMNA (0.68) | LMNAHSD17B10KMT2AMEN1ALDH1A1 | |
| SCHEMBL5040020 | 1.00 | LMNA (0.68) | LMNAHSD17B10KMT2AMEN1ALDH1A1 | |
| SCHEMBL2933864 | 1.00 | LMNA (0.68) | LMNAHSD17B10KMT2AMEN1ALDH1A1 | |
| SCHEMBL21065749 | 1.00 | LMNA (0.68) | LMNAHSD17B10KMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150174062-A1 | BIODEGRADABLE DRUG DELIVERY SYSTEM | ALLERGAN, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-8956655-B2 | Biodegradable drug delivery system | ALLERGAN, INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-8759391-B2 | Topical anesthetic for rapid local anesthesia | JUVENTIO, LLC (US) | 2014-06-24 | — | — | US | disclosed |
| US-8506962-B2 | Sustained release drug delivery systems comprising a water soluble therapeutic agent and a release modifier | ALLERGAN, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-20130034550-A1 | Sustained release drug delivery systems comprising a water soluble therapeutic agent and a release modifier | ALLERGAN, INC (US) | 2013-02-07 | — | — | US | disclosed |
| US-8318169-B2 | Sustained release drug delivery systems comprising a water soluble therapeutic agent and a release modifier | ALLERGEN, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20120263779-A1 | BIODEGRADABLE DRUG DELIVERY SYSTEM | ALLERGAN, INC. | 2012-10-18 | — | — | US | disclosed |
| US-8231892-B2 | Biodegradable drug delivery system | ALLERGAN, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-20080292679-A1 | BIODEGRADABLE DRUG DELIVERY SYSTEM | ALLERGAN, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080176948-A1 | Topical Anesthetic for Rapid Local Anesthesia and Method of Applying a Topical Anesthetic | DERMWORX, INC. (US) | 2008-07-24 | — | — | US | disclosed |
| US-20080107694-A1 | Glycolic acid-lactic acid copolymer; biocompatible; biodegradable; RNA interference; inhibitors of vascular endothelial growth factor (VEGF); ocular disorders | ALLERGAN, INC. (US) | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080107694-A1 | Glycolic acid-lactic acid copolymer; biocompatible; biodegradable; RNA interference; inhibitors of vascular endothelial growth factor (VEGF); ocular disorders | VEGFA, KDR, FLT1 | LMNA 1555/4885HSD17B10 2170/4885KMT2A 4047/4885 |
| US-20130034550-A1 | Sustained release drug delivery systems comprising a water soluble therapeutic agent and a release modifier | VEGFA, HDGF, CRYAA | LMNA 1193/4885HSD17B10 3876/4885KMT2A 4327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.